Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II - PubMed (original) (raw)
Randomized Controlled Trial
. 2009 Nov;18(11):2835-41.
doi: 10.1158/1055-9965.EPI-09-0596. Epub 2009 Oct 20.
Affiliations
- PMID: 19843681
- DOI: 10.1158/1055-9965.EPI-09-0596
Randomized Controlled Trial
Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Janet S Hildebrand et al. Cancer Epidemiol Biomarkers Prev. 2009 Nov.
Abstract
The Women's Health Initiative randomized trials showed a reduction in colorectal cancer risk with the use of estrogen plus progesterone (E + P), but not with estrogen alone (E-only), after intervention periods <7 years. Using data from the Cancer Prevention Study II Nutrition Cohort, we examined associations of colorectal cancer risk with E-only and E + P, including analyses by recency and duration of hormone use. During 13.2 years of follow-up, 776 cases of invasive colorectal cancer occurred among 67,412 postmenopausal women participants. Cox proportional hazards models were used to estimate multivariate-adjusted relative risks (RR) and 95% confidence intervals (95% CI) of colorectal cancer for current and former hormone users according to hormone type and duration of use. Relative to women who never used postmenopausal hormones, current, but not former, use of E-only was associated with a reduced risk of colorectal cancer (RR 0.76; 95% CI, 0.59-0.97). Among current E-only users, duration of use was inversely and linearly associated with risk (P(trend) = 0.01). Use of E-only for <5 years was not associated with reduced risk, whereas use for >or=20 years was associated with a 45% reduction in risk (RR, 0.55; 95% CI, 0.36-0.86). There were no statistically significant associations between E + P and colorectal cancer risk. Our results suggest a strong inverse association of long-term use of E-only with colorectal cancer risk, underscoring the importance of collecting data on duration of hormone use in epidemiologic studies of postmenopausal hormones and risk of disease.
Similar articles
- Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C. Anderson GL, et al. Maturitas. 2006 Sep 20;55(2):103-15. doi: 10.1016/j.maturitas.2006.05.004. Epub 2006 Jul 11. Maturitas. 2006. PMID: 16815651 Clinical Trial. - Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort.
Rodriguez C, Spencer Feigelson H, Deka A, Patel AV, Jacobs EJ, Thun MJ, Calle EE. Rodriguez C, et al. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):655-60. doi: 10.1158/1055-9965.EPI-07-2683. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18349283 - Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, Gansler T, Thun MJ, Calle EE. McCullough ML, et al. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):73-9. doi: 10.1158/1055-9965.EPI-07-2567. Epub 2008 Jan 9. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18187388 - Breast cancer risk with postmenopausal hormonal treatment.
Collins JA, Blake JM, Crosignani PG. Collins JA, et al. Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. doi: 10.1093/humupd/dmi028. Epub 2005 Sep 8. Hum Reprod Update. 2005. PMID: 16150813 Review. - Colorectal cancer in women: hormone replacement therapy and chemoprevention.
Barnes EL, Long MD. Barnes EL, et al. Climacteric. 2012 Jun;15(3):250-5. doi: 10.3109/13697137.2012.659450. Climacteric. 2012. PMID: 22612611 Review.
Cited by
- The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study.
Nam JH, Jang SI, Park HS, Kim JH, Lee JK, Lim YJ, Koh MS, Lee JH, Park S, Nam CM, Park EC. Nam JH, et al. BMC Gastroenterol. 2021 Nov 23;21(1):440. doi: 10.1186/s12876-021-02021-y. BMC Gastroenterol. 2021. PMID: 34814853 Free PMC article. - Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis.
Harewood R, Disney R, Kinross J, von Wagner C, Cross AJ. Harewood R, et al. Cancer Causes Control. 2021 Oct;32(10):1047-1061. doi: 10.1007/s10552-021-01472-8. Epub 2021 Jul 5. Cancer Causes Control. 2021. PMID: 34224060 Free PMC article. Review. - Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.
Božović A, Mandušić V, Todorović L, Krajnović M. Božović A, et al. Int J Mol Sci. 2021 Feb 6;22(4):1656. doi: 10.3390/ijms22041656. Int J Mol Sci. 2021. PMID: 33562134 Free PMC article. Review. - Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors.
Rawla P, Sunkara T, Barsouk A. Rawla P, et al. Prz Gastroenterol. 2019;14(2):89-103. doi: 10.5114/pg.2018.81072. Epub 2019 Jan 6. Prz Gastroenterol. 2019. PMID: 31616522 Free PMC article. Review. - Mismatch Repair Protein hMLH1, but not hMSH2, Enhances Estrogen-Induced Apoptosis of Colon Cancer Cells.
Jin P, Wang DZ, Lyu CX, Wang YT, He YQ, Sheng JQ, Li X. Jin P, et al. J Cancer. 2017 Sep 15;8(16):3232-3241. doi: 10.7150/jca.20833. eCollection 2017. J Cancer. 2017. PMID: 29158795 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical